ストックスクリーナーアプリを入手
96.72
5.27%
4.84
アフターアワーズ：
96.15
-0.57
-0.59%
前日終値:
$91.88
開ける：
$92.3
24時間の取引高:
5.10M
Relative Volume:
1.64
時価総額：
$20.96B
収益：
$819.56M
当期純損益:
$-1.18B
株価収益率:
-16.84
EPS:
-5.7434
ネットキャッシュフロー:
$-951.64M
1週間 パフォーマンス:
-7.82%
1か月 パフォーマンス:
-6.90%
6か月 パフォーマンス:
-50.46%
1年 パフォーマンス:
-1.29%
1日の値動き範囲:
$91.37
$98.18
1週間の範囲:
$90.39
$105.00
52週間の値動き範囲:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Compare INSM vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
96.72 | 19.92B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
445.04 | 110.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.48 | 63.08B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
898.94 | 53.62B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
289.39 | 38.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 30.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Raymond James | Outperform |
| 2026-03-30 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2026-01-23 | 開始されました | Roth Capital | Buy |
| 2025-12-19 | 再開されました | Truist | Buy |
| 2025-12-04 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-10-28 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-08-20 | 開始されました | William Blair | Outperform |
| 2025-08-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 開始されました | Jefferies | Buy |
| 2025-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-04-23 | 開始されました | Truist | Buy |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-07-26 | 開始されました | Guggenheim | Buy |
| 2022-12-09 | 開始されました | Mizuho | Buy |
| 2022-12-07 | 開始されました | Barclays | Overweight |
| 2022-11-18 | 開始されました | BofA Securities | Buy |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2021-12-06 | 開始されました | JP Morgan | Overweight |
| 2021-10-19 | 再開されました | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-10-12 | 再開されました | Stifel | Buy |
| 2019-09-03 | 開始されました | Goldman | Buy |
| 2019-04-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-15 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2019-01-02 | 開始されました | Canaccord Genuity | Buy |
| 2018-08-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 開始されました | Goldman | Neutral |
| 2018-04-23 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 開始されました | Morgan Stanley | Overweight |
| 2018-01-18 | 開始されました | Credit Suisse | Neutral |
| 2017-09-05 | 繰り返されました | Evercore ISI | Outperform |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-07-11 | 開始されました | Robert W. Baird | Outperform |
| 2016-03-15 | 開始されました | Stifel | Buy |
| 2015-11-09 | ダウングレード | UBS | Buy → Neutral |
| 2015-10-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-06-09 | 開始されました | Citigroup | Neutral |
| 2014-03-26 | 繰り返されました | HC Wainwright | Buy |
すべてを表示
Insmed Inc (INSM) 最新ニュース
Insmed stock hits 52-week low at 90.85 USD By Investing.com - Investing.com Nigeria
Daily Brief Health Care: Laurus Labs, Ascendis Pharma, GSK , Incyte Corp, Insmed Inc, Johnson & Johnson, Kardigan, LogicMark, Parabilis Medicines, Solventum and more - Smartkarma
Insmed slides 7.9% as risk-off tape collides with pipeline-focused positioning ahead of TPIP data - Quiver Quantitative
[Form 4] INSMED Inc Insider Trading Activity - Stock Titan
Insmed stock hits 52-week low at 90.85 USD - Investing.com
Stock Traders Purchase High Volume of Call Options on Insmed (NASDAQ:INSM) - MarketBeat
Cantor Fitzgerald reiterates Insmed stock rating on TPIP data outlook - Investing.com UK
Cantor Fitzgerald reiterates Insmed stock rating on TPIP data outlook By Investing.com - Investing.com Nigeria
Insmed Inc stock (US4576693075): pipeline update and growth story in rare diseases - AD HOC NEWS
INSM: Brensocatib’s stellar launch and expanding pipeline set the stage for sustained growth - TradingView
Insmed Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
INSM Maintained by JP Morgan -- Price Target Lowered to $179 - GuruFocus
Insmed (INSM) Remains a Strong Buy Despite Recent Stock Decline - GuruFocus
William Lewis files Form 144 — INSM insider sale notice (INSM) - Stock Titan
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
JPMorgan Chase & Co. Cuts Insmed (NASDAQ:INSM) Price Target to $179.00 - MarketBeat
Is Insmed (INSM) The Best Healthcare Stock to Buy Now? - Yahoo Finance
ING Groep NV Sells 250,555 Shares of Insmed, Inc. $INSM - MarketBeat
Fiera Capital Corp Raises Stock Position in Insmed, Inc. $INSM - MarketBeat
Clearbridge Investments LLC Has $142.54 Million Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases Shares of 50,500 Insmed, Inc. $INSM - MarketBeat
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Operating income of Insmed Incorporated – XETR:IM8N - TradingView
Return on equity % of Insmed Incorporated – XETR:IM8N - TradingView
Insmed Incorporated Balance Sheet – XETR:IM8N - TradingView
Is Insmed's (INSM) Brensocatib Momentum Quietly Reframing Its Respiratory Growth Narrative? - Yahoo Finance
Harvest Fund Management Co. Ltd Acquires 14,454 Shares of Insmed, Inc. $INSM - MarketBeat
INSM Maintained by RBC Capital -- Price Target Lowered to $195 - GuruFocus
INSM: Director Martina Flammer reports multiple Rule 144 sales (INSM) - Stock Titan
Insmed Chair, CEO Sold Shares Worth Over $777K - TradingView
INSMED (INSM) COO sells 2,370 shares to cover RSU tax withholding - Stock Titan
Insmed (NASDAQ: INSM) CFO sells 2,404 shares to cover RSU taxes - Stock Titan
INSMED (INSM) legal chief sells 2,159 shares to cover RSU tax - Stock Titan
Insmed (INSM) CMO sells 4,424 shares for tax withholding under plan - Stock Titan
Insmed Brinsupri Shows Strong Physician Conviction, Early Launch Momentum, RBC Says - Moomoo
RBC Capital Adjusts Insmed Price Target to $195 From $205, Maintains Outperform Rating - Moomoo
RBC Capital lowers Insmed stock price target to $195 on model refinement - Investing.com UK
Insmed Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - marketscreener.com
RBC Capital lowers Insmed stock price target to $195 on model refinement By Investing.com - Investing.com South Africa
Insmed earnings up next: Can Brinsupri sustain blockbuster launch? - Investing.com
Insmed earnings up next: Can Brinsupri sustain blockbuster launch? By Investing.com - Investing.com Nigeria
UBS Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $166 - Moomoo
Insmed (INSM) Grants Equity Awards to New Employees Amid Growth Phase - GuruFocus
Insmed CEO William Lewis sells $1.47m in company stock - Investing.com
Insmed Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com
103 new hires at Insmed get stock, options inducement grants - Stock Titan
Wells Fargo Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $160 - Moomoo
INSM (NASDAQ) notice: director sale 8,272 shares; stock plan activity - Stock Titan
Martina Flammer proposes share sales at INSM (INSM) - Stock Titan
Insmed Inc (INSM) 財務データ
収益
当期純利益
現金流量
EPS
4.65%
1.27%
大文字化:
|
ボリューム (24 時間):